AbbVie Adjusts 2024 Earnings Forecast
AbbVie (NYSE: ABBV) has revised its adjusted profit forecast for 2024, primarily due to substantial acquisition expenses. The pharmaceutical giant has reported around $1.6 billion in costs linked to milestone payments and research and development efforts as it strives to enhance its product pipeline.
Impact of Humira's Patent Expiry
Following the expiration of its blockbuster arthritis medication, Humira's patent last year, AbbVie has concentrated on expanding its offerings. This strategy is crucial as Humira has significantly contributed to the company’s revenue, and the loss of exclusivity necessitates effective new product introductions to maintain its market position.
Recent Acquisitions
To bolster its product portfolio, AbbVie completed several major acquisitions, including neuroscience developer Cerevel Therapeutics and cancer drug developer ImmunoGen (NASDAQ: IMGN). The total value of these transactions is over $20 billion, reflecting AbbVie's commitment to diversifying its drug pipeline and maintaining robust innovation.
Financial Forecast Adjustments
AbbVie now expects its adjusted earnings for 2024 to fall between $10.02 and $10.06 per share, a downgrade from its earlier estimate of $10.90 to $10.94. This recent adjustment indicates the company’s proactive approach in managing financial expectations amidst significant upcoming costs and market changes.
Analyst Expectations
Market analysts are currently projecting an average adjusted profit of $10.94 per share for 2024, based on consensus data from LSEG. This mismatch between analyst expectations and AbbVie's revised forecast highlights the challenges the company may face in the near future.
Q4 Adjusted Profit Predictions
For the fourth quarter, AbbVie anticipates an adjusted profit ranging from $2.06 to $2.10 per share. This is in contrast to the $2.79 per share reported during the same period last year, emphasizing the impact of increased acquisition costs on overall profitability.
Upcoming Earnings Report
AbbVie is expected to release its fourth-quarter earnings results on January 31. Stakeholders and investors will be keenly watching this report for further insights into the company's financial health and strategic direction amid these significant changes.
Frequently Asked Questions
What prompted AbbVie to lower its profit forecast for 2024?
The main reason for the revision is the $1.6 billion in acquisition expenses related to new drug development and milestone payments.
Which companies did AbbVie acquire recently?
AbbVie acquired Cerevel Therapeutics, ImmunoGen, and Aliada, totaling over $20 billion, to enhance its drug portfolio.
How much profit does AbbVie expect for Q4?
AbbVie anticipates an adjusted profit of $2.06 to $2.10 per share for the fourth quarter.
When will AbbVie report its fourth-quarter earnings?
AbbVie is scheduled to report its fourth-quarter earnings on January 31.
What impact did Humira's patent expiration have on AbbVie?
The expiration of Humira's patent has prompted AbbVie to focus on expanding its pipeline to offset potential revenue losses from the drug.
